<DOC>
	<DOCNO>NCT00429403</DOCNO>
	<brief_summary>Primary Objective : - To determine effectiveness goserelin acetate ( Zoladex ) preserve ovarian function premenopausal woman undergo neoadjuvant and/or adjuvant chemotherapy primary invasive breast cancer document persistence resumption regular menses . Secondary Objectives : - To determine incidence pregnancy effect participant ' quality life ( QOL ) chemotherapy . - To determine overall survival disease-free survival time study participant .</brief_summary>
	<brief_title>Goserelin Acetate Study Ovarian Function Patients With Primary Breast Cancer</brief_title>
	<detailed_description>Goserelin design block hormone regulate menstruation affect pituitary gland ( part brain ) . If find eligible take part study , randomly assign ( toss coin ) one two treatment group . You either assign receive goserelin treatment . There equal chance assign either group . If assign receive goserelin , first dose give injection skin , 1 week start chemotherapy . You receive chemotherapy part standard care . Following first dose goserelin , give goserelin injection skin , month 3 week last chemotherapy dose . You take study intolerable side effect occur study . After finished chemotherapy , series follow-up visit . During period follow-up , medical history , physical exam , blood test ( 2-3 teaspoon ) evaluate ovarian function , every 3 month 1 year 24 month . You ask fill questionnaire menstrual history visit . The questionnaire take 15 minute complete . You also ask fill questionnaire quality life 12 24 month . The questionnaire take 30 minute complete . This investigational study . Goserelin commercially available approve FDA use breast cancer patient . Its use study investigational . About 148 patient take part multicenter study . Up 36 patient enrol M.D . Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>1 . Female patient older 15 year younger 46 year . 2 . Primary breast cancer ( Stage I , II , III ) . 3 . Pathologically confirm invasive breast carcinoma . 4 . Negative hormonereceptor status . ( Negative define ER PR stain less 10 % tumor cell , tumor less equal 3 fm/mg cytosol protein ligandbinding enzymelinked immunoassay ) . 5 . Premenopausal , verify chemotherapy begin satisfying : Cyclic vaginal bleeding . Folliclestimulating hormone ( FSH ) less equal 15 IU/L . If patient take oral contraceptive , FSH must measure 12 week discontinuation . If FSH great 15 patient regular menses , gynecologic consultation require decision premenopausal status . 6 . Candidates neoadjuvant and/or adjuvant chemotherapy primary breast cancer . 7 . Treatment least four ( 4 ) cycle chemotherapy plan . 8 . Zubrod performance score 0 1 . 9 . Must consent preservation ovarian function indicate awareness investigational nature study , keep institutional policy . 10 . Willingness use barrier contraception sexually active . 1 . Pregnancy . Women must negative serum pregnancy test initiation injection . 2 . Hypersensitivity GnRH analog . 3 . Previous receipt systemic chemotherapy . 4 . To receive least 4 cycle neoadjuvant and/or adjuvant chemotherapy CMF . 5 . Stage IV breast cancer . 6 . Prothrombin time ( PT ) partial prothrombin time ( PTT ) INR &gt; 1.5 7 . Platelets &lt; 50,000/mm^3</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Ovarian Function</keyword>
	<keyword>Goserelin</keyword>
	<keyword>Zoladex</keyword>
	<keyword>Ovary function</keyword>
	<keyword>Fertility</keyword>
	<keyword>Early Menopause</keyword>
</DOC>